A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
Phase of Trial: Phase III
Latest Information Update: 30 Jan 2019
At a glance
- Drugs MDR 101 (Primary)
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Medeor Therapeutics
- 27 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.
- 22 Jan 2018 Steven R. Deitcher is Principal Investigator for this trial, as reported in a Medeor Therapeutics media release.